Trials / Terminated
TerminatedNCT00257881
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CMD-193 |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-12-01
- First posted
- 2005-11-23
- Last updated
- 2007-12-10
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00257881. Inclusion in this directory is not an endorsement.